ClinicalTrials.gg
RecruitingNCT07319832Updated Mar 13, 2026

A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome

An observational study in Short Bowel Syndrome (SBS), sponsored by Takeda. Recruiting at 4 sites in China. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Takeda · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
12
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Short Bowel Syndrome by Takeda — 1 open to participants now, 3 under way, 1 of them phase 3. Short Bowel Syndrome · Takeda.

Started
2026
the only one that year
Observational
8 of 26
1 open now
Registered
26th of 26
by date

Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the only one that started in 2026, is one of 8 observational ones, and was the 26th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 26 studies in Short Bowel Syndrome by Takeda is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Short Bowel Syndrome by Takeda, or all of them as a file.
02

Study summary

Short Bowel Syndrome (SBS) is a rare condition that happens when a large part of the bowel (also called intestine) is missing or has been removed because of illness or surgery. In children, SBS means that the intestine cannot absorb enough food, water and important part of food the body needs (called nutrients) because a big part of it has been removed, bypassed or did not develop normally at birth and the children need support through a vein (parenteral support or PS) for more than 42 days to stay healthy and keep their energy. SBS in children is defined mainly by how well the intestine works and how long the children need this support, not just by how long the intestine is.

The main aim of the study is to learn how well the teduglutide works in children and teenagers with SBS and who need PS. Another aim is to find out how well teduglutide works for participants to lower the amount of PS needed. Also, the study wants to learn more about how safe teduglutide is in children and teenagers with SBS who need PS.

The study will review data already existing in the medical records of participants as well as collect new data during the study.

03

Conditions studied

  • Short Bowel Syndrome (SBS)

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of Chinese pediatric participants with SBS who are dependent on PS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents greater than or equal to (>=)1 through 17 years of age at Day 1 (D1).
  • Documented diagnosis of SBS.
  • Received or plan to receive Teduglutide treatment for a minimum of 24 weeks.
  • Stable PN/IV support, defined as inability to significantly reduce PN/IV support, usually associated with minimal or no advance in enteral feeds (i.e., 10% or less change in PN or advance in feeds) for at least 3 months prior to D1, as assessed by the investigator. Transient instability for events such as interruption of central access or treatment for sepsis is allowed if the PN/IV support returns to within 10% of baseline prior to the event.
  • obtained from the patient aged 8 to 17 years and their guardians, while informed consent from the guardians for participants under 8 years old, unless waived by the Institution's Ethics Committee.

Exclusion criteria

Exclusion criteria

  • Participants who are not expected to be able to advance oral or tube feeding regimens.
  • Serial Transverse Enteroplasty (STEP) or any other bowel lengthening procedure performed within 3 months prior to baseline.
  • Known untreated intestinal obstruction contributing to feeding intolerance and inability to reduce PS.
  • Evidence of clinically significant obstruction on upper GI series done within 6 months prior to baseline.
  • Previous use of octreotide or Dipeptidyl peptidase-4 (DPP-4) inhibitors within 3 months prior to baseline.
  • Signs of active, severe, or unstable clinically significant hepatic impairment during the screening or baseline period, indicative by any of the following laboratory test results:

    1. Total Level (TBL) >= 2 × (ULN)
    2. (AST) >=7 × ULN
    3. Alanine Aminotransferase (ALT) >=7 × ULN

      For Participants with Gilbert's disease:

    4. Indirect (unconjugated) bilirubin >=2 × ULN
  • Signs of known continuous active or unstable, clinically significant renal dysfunction shown by results of an estimated (eGFR) below 50 millilitres per minutes per 1.73 meter square (mL/min/1.73 m\^2).
  • Known of the active substance or of teduglutide.
  • Body weight less than (\<) 10 kg at baseline.
  • Previous use of teduglutide or native/synthetic Glucagon-like Peptide-2 (GLP-2).
  • Previous use of GLP-1 analog or human growth hormone within 3 months prior to baseline.
  • Any condition, disease, illness, or circumstance that in the investigator's opinion puts the patient at any undue risk, prevents completion of the study, or interferes with analysis of the study results.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
12 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective Group

    Participants who completed the 24-week teduglutide treatment period before enrollment will have their clinical data collected retrospectively from their medical records.

    Other: No Intervention

  • Mixed Group

    Participants who initiated treatment before the study start date but have not completed the 24-week teduglutide treatment period at the time of enrollment will have their clinical data collected retrospectively before enrollment and prospectively after enrollment.

    Other: No Intervention

  • Prospective Group

    Participants who will initiate the teduglutide treatment period after enrollment will have their clinical data collected prospectively for 48 weeks.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    No Intervention

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieve at Least a 20% Reduction from Baseline in Weekly Parenteral Support (PS) Volume at Week 24

    Percentage of participants who achieve at least a 20 percent (%) reduction from baseline in weekly PS volume at Week 24 will be reported.

    Time frame: At Week 24

Secondary outcomes

  1. Number of Participants Able to Completely Wean off PS Support at Week 24

    Number of participants who are able to completely wean off PS support at Week 24 will be reported.

    Time frame: At Week 24

  2. Absolute Change from Baseline in PN/Intravenous (IV) Support Volume

    Absolute change from baseline in PN/IV support volume will be reported.

    Time frame: Baseline up to Week 24

  3. Percent Change From Baseline in PN/IV Support Volume

    Percent change from baseline in PN/IV support volume will be reported.

    Time frame: Baseline up to Week 24

  4. Absolute Change From Baseline in PN/IV Support Calories

    Absolute change from baseline in PN/IV support calories will be reported.

    Time frame: Baseline up to Week 24

  5. Percent Change From Baseline in PN/IV Support Calories

    Percent change from baseline in PN/IV support calories will be reported.

    Time frame: Baseline up to Week 24

  6. Absolute Change From Baseline in Plasma Citrulline

    Absolute change from baseline in plasma citrulline will be reported.

    Time frame: Baseline, Week 24

  7. Percent Change From Baseline in Plasma Citrulline

    Percent change from baseline in plasma citrulline will be reported.

    Time frame: Baseline, Week 24

  8. Absolute Change From Baseline in Enteral Nutrition (EN) Support Volume

    Absolute change from baseline in EN support volume will be reported.

    Time frame: Baseline up to Week 24

  9. Percent Change From Baseline in EN Support Volume

    Percent change from baseline in EN support volume will be reported.

    Time frame: Baseline up to Week 24

  10. Absolute Change From Baseline in EN Support Calories

    Absolute change from baseline in EN support calories will be reported.

    Time frame: Baseline up to Week 24

  11. Percent Change From Baseline in EN Support Calories

    Percent change from baseline in EN support calories will be reported.

    Time frame: Baseline up to Week 24

  12. Change From Baseline in Hours per day of PN/IV Support

    Change from baseline in hours per day of PN/IV support will be reported.

    Time frame: Baseline up to Week 24

  13. Change From Baseline in Days per Week of PN/IV Support

    Change from baseline in days per week of PN/IV support will be reported.

    Time frame: Baseline up to Week 24

  14. Percentage of Participants with at Least a 20% Reduction From Baseline in PN/IV Volume

    Percentage of participants with at least a 20% reduction from baseline in PN/IV volume will be reported.

    Time frame: Baseline up to Week 24

  15. Change in Body Weight

    Change in body weight will be reported.

    Time frame: Baseline up to Week 24

  16. Change in Height

    Change in height will be reported.

    Time frame: Baseline up to Week 24

  17. Change in Head Circumference

    Head circumference will be measured in participants 36 months of age and younger.

    Time frame: Baseline up to Week 24

  18. Change in Height Z-score

    Height is measured using Z-score. Z score is calculated as (\[observed value/M\]\^L-1)/S\*L, where observed value is the child's height. The L, M, and S values vary according to the child's sex and age.

    Time frame: Baseline up to Week 24

  19. Change in Weight Z-score

    Weight is measured using Z-score. Z score is calculated as (\[observed value/M\]\^L-1)/S\*L, where observed value is the child's weight. The L, M, and S values vary according to the child's sex and age.

    Time frame: Baseline up to Week 24

  20. Change in Body Mass Index (BMI)

    BMI is a simple measure that uses a participant's weight and height to estimate whether they are underweight, normal weight, overweight, or obese. It is calculated as weight in kilograms (kg) divided by height in meters squared (kg/m\^2). Change in BMI will be reported.

    Time frame: Baseline up to Week 24

  21. Change in BMI Z-score

    BMI is measured using Z-score. Z score is calculated as (\[observed value/M\]\^L-1)/S\*L, where observed value is the child's BMI. The L, M, and S values vary according to the child's sex and age.

    Time frame: Baseline up to Week 24

  22. Number of Participants with Adverse Events (AEs). Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have a causal relationship withthis treatment. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product (investigational or marketed), whether or not considered related to treatment with the medicinal product. SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, or is an important medical event. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the product or program.

    Time frame: Up to 50 weeks

  23. Number of Participants with Clinically Significant Change in Vital Sign Values

    Vital signs will include measurement of temperature, heart rate, blood pressure and respiratory rate. Any clinically significant change in vital signs will be determined at the investigator's discretion.

    Time frame: Up to 24 weeks

  24. Body Weight in Participants Dependent on PS

    Body weight in kg will be collected and reported.

    Time frame: Baseline up to Week 24

  25. Head Circumference in Participants Dependent on PS

    Head circumference in participants 36 months of age and younger will be collected and reported.

    Time frame: Baseline up to Week 24

  26. Height in Participants Dependent on PS

    Height in centimeters (cm) will be collected and reported.

    Time frame: Baseline up to Week 24

  27. Trends on Growth Chart

    Trends on growth chart will be collected and reported.

    Time frame: Baseline up to Week 24

  28. Urine Output Determined up to Week 24

    Collected and calculated values of urine output will be recorded over a 48-hour period of PN/IV and EN stability before every clinic visit and within 1 week of implementing a change in the PN/IV prescription.

    Time frame: Baseline up to Week 24

  29. Fecal Output Measured by Volume

    Collected and calculated values of fecal output should be recorded over a 48-hour period of PN/IV and EN stability before every clinic visit and within 1 week of implementing a change in the PN/IV prescription.

    Time frame: Baseline up to Week 24

  30. Fecal Output Measured by Number of Bowel Movements per Day

    Fecal output should be recorded over a 48-hour period of PN/IV and EN stability before every clinic visit and within 1 week of implementing a change in the PN/IV prescription.

    Time frame: Baseline up to Week 24

  31. Number of Participants with Gastrointestinal-specific Testing

    Gastrointestinal-specific testing will include colonoscopy or sigmoidoscopy or upper gastrointestinal (GI) endoscopy, abdominal ultrasound, fecal occult blood testing (FOBT), upper gastrointestinal series small bowel follow-through (UGI SBFT).

    Time frame: Baseline up to Week 24

  32. Number of Participants With Clinically Significant Changes in Physical Examinations

    Physical examination will include assessing the participants physical status. (general surface, skin, head and neck, chest \[heart, lungs, breasts\], abdomen \[gastrointestinal, liver and gallbladder\], back, urinary system, limbs, nervous system, lymph nodes, etc.). Any clinically significant change in physical examination will be determined at the investigator's discretion.

    Time frame: Up to 24 weeks

  33. Number of Participants With Clinically Significant Changes in Laboratory Values

    Laboratory parameters will include hematology, chemistry and urinalysis. Any clinically significant change in laboratory values will be determined at the investigator's discretion.

    Time frame: Up to 24 weeks

  34. Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Parameters

    The 12-lead ECG will be evaluated. Any clinically significant change in ECG assessment will be determined at the investigator's discretion.

    Time frame: Up to 24 weeks

07

Study locations

1 of 4 sites recruiting
  • Guangzhou Women And Children's Medical Center
    Guangzhou, Guangdong 510040, China
    Not yet recruiting
    • Jiakang Yu · Principal investigator
  • Shanghai Children's Hospital
    Shanghai, Shanghai Municipality 200062, China
    Not yet recruiting
    • Zhibao Lv · Principal investigator
  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200092, China
    Recruiting
    • Fan Lv · Principal investigator
  • Children's Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310006, China
    Not yet recruiting
    • Jinfa Tou · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 6, 2026
StartActual
Mar 5, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07319832
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Mar 5, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Mar 13, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion